Visualization of Nigrosome 1 from the Viewpoint of Anatomic Structure

References

1. 1.↵
   1. Péran P,
   2. Cherubini A,
   3. Assogna F, et al

   . Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 2010;133:3423–33 doi:10.1093/brain/awq212 pmid:20736190

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Brass SD,
   2. Chen NK,
   3. Mulkern RV, et al

   . Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 2006;17:31–40 doi:10.1097/01.rmr.0000245459.82782.e4 pmid:17179895

   CrossRefPubMed
3. 3.↵
   1. Berg D,
   2. Youdim MB

   . Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 2006;17:5–17 doi:10.1097/01.rmr.0000245461.90406.ad pmid:17179893

   CrossRefPubMed
4. 4.↵
   1. Griffiths PD,
   2. Dobson BR,
   3. Jones GR, et al

   . Iron in the basal ganglia in Parkinson’s disease: an in vitro study using extended x-ray absorption fine structure and cryo-electron microscopy. Brain 1999;122:667–73 doi:10.1093/brain/122.4.667 pmid:10219780

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Graham JM,
   2. Paley MN,
   3. Grünewald RA, et al

   . Brain iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence. Brain 2000;123 Pt 12:2423–31 doi:10.1093/brain/123.12.2423 pmid:11099445

   CrossRefPubMed
6. 6.↵
   1. Griffiths PD,
   2. Crossman AR

   . Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson’s disease and Alzheimer’s disease. Dementia 1993;4:61–65 doi:10.1159/000107298 pmid:8358514

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Sedlacik J,
   2. Boelmans K,
   3. Lobel U, et al

   . Reversible, irreversible and effective transverse relaxation rates in normal aging brain at 3T. Neuroimage 2014;84:1032–41 doi:10.1016/j.neuroimage.2013.08.051 pmid:24004692

   CrossRefPubMed
8. 8.↵
   1. Aquino D,
   2. Bizzi A,
   3. Grisoli M, et al

   . Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 2009;252:165–72 doi:10.1148/radiol.2522081399 pmid:19561255

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Blazejewska AI,
   2. Schwarz ST,
   3. Pitiot A, et al

   . Visualization of nigrosome 1 and its loss in PD: pathoanatomic correlation and in vivo 7 T MRI. Neurology 2013;81:534–40 doi:10.1212/WNL.0b013e31829e6fd2 pmid:23843466

   Abstract/FREE Full Text
10. 10.↵
    1. Damier P,
    2. Hirsch EC,
    3. Agid Y, et al

    . The substantia nigra of the human brain, II: patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999;122:1437–48 doi:10.1093/brain/122.8.1437 pmid:10430830

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Cosottini M,
    2. Frosini D,
    3. Pesaresi I, et al

    . Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol 2015;36:461–66 doi:10.3174/ajnr.A4158 pmid:25376811

    Abstract/FREE Full Text
12. 12.↵
    1. Damier P,
    2. Hirsch EC,
    3. Agid Y, et al

    . The substantia nigra of the human brain, I: nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122:1421–36 doi:10.1093/brain/122.8.1421 pmid:10430829

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Schwarz ST,
    2. Afzal M,
    3. Morgan PS, et al

    . The ‘swallow tail’ appearance of the healthy nigrosome: a new accurate test of Parkinson’s disease—a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814 doi:10.1371/journal.pone.0093814 pmid:24710392

    CrossRefPubMed
14. 14.↵
    1. Wallis LI,
    2. Paley MN,
    3. Graham JM, et al

    . MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J Magn Reson Imaging 2008;28:1061–67 doi:10.1002/jmri.21563 pmid:18972346

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Noh Y,
    2. Sung YH,
    3. Lee J, et al

    . Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality. AJNR Am J Neuroradiol 2015;36:2010–06 doi:10.3174/ajnr.A4412 pmid:26294646

    Abstract/FREE Full Text
16. 16.↵
    1. Nam Y,
    2. Gho SM,
    3. Kim DH, et al

    . Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI). J Magn Reson Imaging 2017;46:528–36 doi:10.1002/jmri.25553 pmid:27859983

    CrossRefPubMed
17. 17.↵
    1. Bilgic B,
    2. Pfefferbaum A,
    3. Rohlfing T, et al

    . MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012;59:2625–35 doi:10.1016/j.neuroimage.2011.08.077 pmid:21925274

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Lee J,
    2. Nam Y,
    3. Choi JY, et al

    . Mechanisms of T2 * anisotropy and gradient echo myelin water imaging. NMR Biomed 2017;30 [Epub 2016 Apr 7] doi:10.1002/nbm.3513 pmid:27060968

    CrossRefPubMed
19. 19.↵
    1. Puwal S,
    2. Roth BJ,
    3. Basser PJ

    . Heterogeneous anisotropic magnetic susceptibility of the myelin-water layers causes local magnetic field perturbations in axons. NMR Biomed 2017;30 doi:10.1002/nbm.3628 pmid:27731911

    CrossRefPubMed
20. 20.↵
    1. Aggarwal M,
    2. Kageyama Y,
    3. Li X, et al

    . B₀-orientation dependent magnetic susceptibility-induced white matter contrast in the human brainstem at 11.7T. Magn Reson Med 2016;75:2455–63 doi:10.1002/mrm.26208 pmid:27018784

    CrossRefPubMed
21. 21.↵
    1. Wu B,
    2. Li W,
    3. Guidon A, et al

    . Whole brain susceptibility mapping using compressed sensing. Magn Reson Med 2012;67:137–47 doi:10.1002/mrm.23000 pmid:21671269

    CrossRefPubMed
22. 22.↵
    1. Khabipova D,
    2. Wiaux Y,
    3. Gruetter R, et al

    . A modulated closed form solution for quantitative susceptibility mapping: a thorough evaluation and comparison to iterative methods based on edge prior knowledge. Neuroimage 2015;107:163–74 doi:10.1016/j.neuroimage.2014.11.038 pmid:25463463

    CrossRefPubMed
23. 23.↵
    1. Li W,
    2. Wang N,
    3. Yu F, et al

    . A method for estimating and removing streaking artifacts in quantitative susceptibility mapping. Neuroimage 2015;108:111–22 doi:10.1016/j.neuroimage.2014.12.043 pmid:25536496

    CrossRefPubMed
24. 24.↵
    1. Erickson SJ,
    2. Prost RW,
    3. Timins ME

    . The “magic angle” effect: background physics and clinical relevance. Radiology 1993;188:23–25 doi:10.1148/radiology.188.1.7685531 pmid:7685531

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Chappell KE,
    2. Robson MD,
    3. Stonebridge-Foster A, et al

    . Magic angle effects in MR neurography. AJNR Am J Neuroradiol 2004;25:431–40 pmid:15037469

    Abstract/FREE Full Text
26. 26.↵
    1. Kan H,
    2. Arai N,
    3. Kasai H, et al

    . Quantitative susceptibility mapping using principles of echo shifting with a train of observations sequence on 1.5T MRI. Magn Reson Imaging 2017;42:37–42 doi:10.1016/j.mri.2017.05.002 pmid:28526432

    CrossRefPubMed
27. 27.↵
    1. Wang Y,
    2. Liu T

    . Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 2015;73:82–101 doi:10.1002/mrm.25358 pmid:25044035

    CrossRefPubMed
28. 28.↵
    1. Liu J,
    2. Liu T,
    3. de Rochefort L, et al

    . Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. Neuroimage 2012;59:2560–68 doi:10.1016/j.neuroimage.2011.08.082 pmid:21925276

    CrossRefPubMed
29. 29.↵
    1. de Rochefort L,
    2. Liu T,
    3. Kressler B, et al

    . Quantitative susceptibility map reconstruction from MR phase data using Bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194–206 doi:10.1002/mrm.22187 pmid:19953507

    CrossRefPubMed
30. 30.↵
    1. Abe O,
    2. Aoki S,
    3. Hayashi N, et al

    . Normal aging in the central nervous system: quantitative MR diffusion-tensor analysis. Neurobiol Aging 2002;23:433–41 doi:10.1016/s0197-4580(01)00318-9 pmid:11959406

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Le Bihan D,
    2. Mangin JF,
    3. Poupon C, et al

    . Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001;13:534–46 doi:10.1002/jmri.1076 pmid:11276097

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Vaillancourt DE,
    2. Spraker MB,
    3. Prodoehl J, et al

    . High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378–84 doi:10.1212/01.wnl.0000340982.01727.6e pmid:19129507

    Abstract/FREE Full Text
33. 33.↵
    1. Yoshikawa K,
    2. Nakata Y,
    3. Yamada K, et al

    . Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry 2004;75:481–84 doi:10.1136/jnnp.2003.021873 pmid:14966170

    Abstract/FREE Full Text
34. 34.↵
    1. Fujiwara S,
    2. Uhrig L,
    3. Amadon A, et al

    . Quantification of iron in the non-human primate brain with diffusion-weighted magnetic resonance imaging. Neuroimage 2014;102:789–97 doi:10.1016/j.neuroimage.2014.08.049 pmid:25192653

    CrossRefPubMed
35. 35.↵
    1. Ogawa S,
    2. Menon RS,
    3. Tank DW, et al

    . Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging: a comparison of signal characteristics with a biophysical model. Biophys J 1993;64:803–12 doi:10.1016/S0006-3495(93)81441-3 pmid:8386018

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Cherubini A,
    2. Peran P,
    3. Hagberg GE, et al

    . Characterization of white matter fiber bundles with T2* relaxometry and diffusion tensor imaging. Magn Reson Med 2009;61:1066–72 doi:10.1002/mrm.21978 pmid:19253372

    CrossRefPubMedWeb of Science